Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Prospective, Multicenter, Randomized, No-Treatment Controlled, Evaluator-Blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of a Medical Collagen Filler for Correcting Infraorbital Depression

Infraorbital hollowing, also known as tear trough deformity, refers to a sunken groove extending from the medial canthal region along the infraorbital rim downward and laterally. It is one of the key features of facial aging and remains one of the most challenging issues in periorbital rejuvenation [1,2]. This deformity is particularly common among Asian populations, with approximately 60%-70% of middle-aged individuals presenting with varying degrees of infraorbital hollowing [2]; its incidence increases significantly with age. The formation of infraorbital hollowing results from the combined effects of multiple factors, including anatomical changes, soft tissue atrophy, skin aging, and impaired lymphatic circulation [2]. Beyond compromising facial aesthetics, it creates negative impressions of fatigue, aging, and sternness, which can severely affect patients' psychological well-being and social lives [3]. In recent years, driven by growing demand for facial rejuvenation, infraorbital hollowing correction has become a popular non-surgical aesthetic procedure.

However, due to the complex anatomy of the infraorbital region-characterized by thin skin, abundant vasculature, and fragile lymphatic drainage-traditional fillers are prone to issues such as migration, the Tyndall effect, and prolonged swelling, placing higher demands on both filling materials and injection techniques [4]. Collagen, as a natural biomaterial, offers distinct advantages for infraorbital hollowing correction owing to its excellent biocompatibility, low migration tendency, and light-scattering properties [5]. The mechanism of collagen injection for infraorbital hollowing correction is a complex, multi-stage, and multi-level process that achieves immediate physical volumization and tissue support. Injected collagen replenishes lost volume, forming a soft, cohesive fibrous structure that lifts the depressed area and restores a smooth transition between the lower eyelid and cheek, thereby reducing the hollowed appearance [5,6]. Meanwhile, due to its high adhesiveness, collagen binds loosened skin tissues together, repositions the disrupted fibrous scaffold network, and restores a youthful, firm contour [6]. After injection, the collagen gradually dehydrates and condenses, reorganizing into a fibrillar structure resembling native collagen in vivo, which further tightens tissues and enhances the supporting effect.

The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. was approved for marketing by the NMPA in 2016 (Registration Certificate No.: Guo Xie Zhu Zhun 20163131609). It is indicated for dermal filling of the face to correct moderate to severe nasolabial folds, and has demonstrated favorable efficacy and safety in clinical practice. The proposed new indication is infraorbital filling for the improvement and correction of infraorbital hollowing. The objective of this study is to evaluate the efficacy and safety of this medical collagen filler manufactured by Feifan (Changchun) Medical Biotechnology Co., Ltd. in correcting the severity of infraorbital hollowing. In accordance with the Measures for the Administration of Medical Device Registration and Filing, the Good Clinical Practice for Medical Device Clinical Trials (GCP), and the Guidelines for Medical Device Clinical Trial Design, and adhering to the ethical principles of the World Medical Association Declaration of Helsinki, this study strives to maximize benefits for research participants while minimizing potential harm.

Przegląd badań

Status

Jeszcze nie rekrutacja

Typ studiów

Interwencyjne

Zapisy (Szacowany)

171

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Aged 18 years or older (based on the time of signing the informed consent form), of any gender; Assessed by the blinded investigator, both eyes must exhibit moderate to severe infraorbital hollowing (i.e., an Allergan Infraorbital Hollowing Scale [AIHS] grade of 2-3), and the participant must desire improvement in the infraorbital hollowing; Able to complete the efficacy self-assessment without wearing framed glasses (wearing contact lenses for self-assessment is acceptable); Able and willing to follow the investigator's instructions, comply with the treatment restrictions specified in this protocol, and attend all scheduled study visits; Voluntarily participating in this clinical trial and signing the research participant informed consent form.

Exclusion Criteria:

  • 1. Known allergy to collagen, any component of the investigational product, or any local anesthetic (e.g., lidocaine or other amide-type anesthetics); 2. History of severe allergic reactions (e.g., anaphylactic shock, laryngeal edema, asthma, dyspnea, hypotension, syncope shortly after exposure to an allergen); 3. Presence of scars, deformities, unhealed wounds, or other conditions in the planned injection area and bilateral midface that may interfere with efficacy evaluation or increase treatment risk, potentially compromising visual assessment of the infraorbital rim, or active/recurrent inflammation or infection in either eye; 4. Previous treatment with any permanent filler (e.g., polymethylmethacrylate [PMMA], silicone, expanded polytetrafluoroethylene [ePTFE]), autologous fat, or unknown injectables in the planned injection area and bilateral midface; 5. Treatment with poly-L-lactic acid (PLLA), polycaprolactone (PCL), calcium hydroxylapatite (CaHA), or similar agents in the planned injection area and bilateral midface within 24 months prior to screening or planned during the trial period; 6. Treatment with cross-linked sodium hyaluronate, animal-derived collagen, or similar agents in the planned injection area and bilateral midface within 12 months prior to screening or planned during the trial period; 7. Treatment with recombinant human-like collagen, botulinum toxin, or similar agents in the planned injection area and bilateral midface within 6 months prior to screening or planned during the trial period; 8. History of active autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis); 9. Treatment with non-cross-linked sodium hyaluronate filler or cosmetic procedures (e.g., intense pulsed light [IPL], radiofrequency, dermabrasion, laser, chemical peels) in the planned injection area and bilateral midface within 6 months prior to screening; 10. Previous lower blepharoplasty or facial lift/brow lift within 12 months prior to screening; 11. In the investigator's judgment, presence of large lower eyelid fat pads affecting treatment or excessive pigmentation in the infraorbital area (excluding dark circles not caused by hyperpigmentation); 12. History of keloids or keloid-prone constitution (hypertrophic scarring tendency); 13. Chemotherapy, immunosuppressants, immunomodulatory therapy (e.g., monoclonal antibodies), or systemic corticosteroids (except inhaled corticosteroids) within 3 months prior to screening; 14. Screening liver function tests showing ALT and/or AST > 2 × upper limit of normal (ULN), or renal function tests showing Cr > 1.5 × ULN, and deemed by the investigator as unsuitable for the trial; 15. History of bleeding disorders (e.g., porphyria, coagulation factor deficiency, coagulopathy, or platelet disorders); clinically significant abnormal coagulation function at screening (e.g., APTT > 1.5 × ULN); or receipt of anticoagulant, antiplatelet, or thrombolytic therapy (e.g., warfarin, heparin, aspirin) within 2 weeks prior to screening; 16. In the investigator's judgment, severe dysfunction of vital organs (e.g., brain, heart, lung, liver, kidney), such as severe cardiovascular or cerebrovascular diseases (hospitalization for myocardial infarction or cardiac surgery, congestive heart failure, or myocardial infarction within 3 months; severe unstable arrhythmia; hypertrophic cardiomyopathy; severe aortic stenosis; aneurysm; stroke), severe pulmonary diseases (moderate to severe pneumonia, respiratory failure), or uncontrolled diabetes; 17. Epilepsy, mental disorders, or other severe neuropsychiatric conditions that may preclude completion of trial follow-up; 18. Lactating women or those planning pregnancy during the study period; 19. Participation in another interventional clinical trial within 1 month prior to screening; 20. Any other condition that, in the investigator's opinion, makes the participant unsuitable for this clinical trial.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Varying degrees of Infraorbital Depression

The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores
Ramy czasowe: 3 months after the last injection in the experimental group and at 3 months after randomization in the control group

The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores at 3 months after the last injection in the experimental group and at 3 months after randomization in the control group, as evaluated by blinded investigator

3 months after the last injection in the experimental group and at 3 months after randomization in the control group

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

25 grudnia 2026

Zakończenie podstawowe (Szacowany)

25 lipca 2027

Ukończenie studiów (Szacowany)

25 lipca 2028

Daty rejestracji na studia

Pierwszy przesłany

13 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

18 listopada 2026

Pierwszy wysłany (Rzeczywisty)

20 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

20 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

18 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • FimanPharma-Xuanwu Hospital

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Tak

produkt wyprodukowany i wyeksportowany z USA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj